Moderna, Inc. Expected to Post FY2024 Earnings of ($9.53) Per Share (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Zacks Research dropped their FY2024 EPS estimates for shares of Moderna in a research report issued on Wednesday, September 11th. Zacks Research analyst S. Ganoria now expects that the company will earn ($9.53) per share for the year, down from their previous forecast of ($9.38). The consensus estimate for Moderna’s current full-year earnings is ($9.52) per share. Zacks Research also issued estimates for Moderna’s Q4 2024 earnings at ($1.30) EPS, Q2 2025 earnings at ($3.39) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($8.74) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.10) EPS and FY2026 earnings at ($6.06) EPS.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same period last year, the firm posted ($3.62) EPS.

Several other brokerages have also commented on MRNA. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Piper Sandler dropped their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Finally, Evercore ISI reiterated an “in-line” rating and set a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $108.53.

Moderna Stock Performance

Shares of Moderna stock opened at $68.28 on Friday. The firm has a market capitalization of $26.17 billion, a P/E ratio of -4.36 and a beta of 1.67. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $95.06 and a 200 day moving average price of $111.68. Moderna has a 52 week low of $62.55 and a 52 week high of $170.47.

Insider Activity

In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Insiders sold a total of 108,158 shares of company stock valued at $13,239,712 over the last three months. Insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of hedge funds have recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the 2nd quarter valued at $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna in the fourth quarter valued at about $27,000. Cedar Wealth Management LLC increased its holdings in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. bought a new stake in Moderna in the first quarter valued at about $32,000. Finally, Family Firm Inc. bought a new stake in shares of Moderna in the second quarter worth about $33,000. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.